Introduction
Glipizide is a potent second-generation sulfonylurea oral hypoglycemic agent (OHA), a first-line pharmaceutical raw material for the clinical management of type 2 diabetes mellitus (T2DM). As a second-generation sulfonylurea derivative, it has a stronger hypoglycemic effect, faster onset of action, and lower incidence of adverse reactions compared with first-generation drugs (e.g., tolbutamide). With a chemical formula of C₂₁H₂₇N₅O₄S, glipizide is formulated into two main clinical preparations: immediate-release tablets and extended-release tablets, adapting to different blood glucose control needs of T2DM patients. It features rapid oral absorption (unaffected by food for extended-release formulations), a moderate half-life (approximately 2–4 hours for immediate-release), and effective regulation of postprandial and fasting blood glucose, with good tolerability at recommended doses. It is widely used in endocrinology and general internal medicine for the long-term blood glucose management of T2DM patients, and is one of the most commonly prescribed sulfonylurea drugs worldwide due to its definite curative effect and low cost.
Core Pharmacological Mechanism (to support its therapeutic uses)
Glipizide exerts its hypoglycemic effect by acting specifically on the sulfonylurea receptor 1 (SUR1) on the membrane of pancreatic β-cells in the islets of Langerhans. This binding closes the ATP-sensitive potassium (KATP) channels on the β-cell membrane, leading to membrane depolarization, subsequent opening of voltage-gated calcium channels, and an influx of extracellular calcium ions into the β-cells. The increased intracellular calcium concentration triggers the exocytosis of insulin-containing secretory granules, thereby promoting the endogenous secretion of insulin in a glucose-dependent manner—this glucose dependence means the drug has a lower risk of hypoglycemia when blood glucose is normal, a key advantage over non-glucose-dependent hypoglycemic agents. In addition to its primary effect on pancreatic β-cells, glipizide also exerts mild auxiliary hypoglycemic effects: it improves insulin sensitivity in peripheral target tissues (skeletal muscle, adipose tissue, and liver), enhances the peripheral utilization of glucose, and reduces hepatic gluconeogenesis and glycogenolysis, further lowering fasting blood glucose levels. Notably, glipizide is only effective in patients with functioning pancreatic β-cells (retaining at least 30% of insulin-secreting capacity), which is a fundamental prerequisite for its clinical application.
Primary Therapeutic Uses
Glipizide is clinically indicated as a first-line oral hypoglycemic drug for the treatment of type 2 diabetes mellitus in adults, suitable for monotherapy or combined therapy, and is mainly used to control fasting and postprandial blood glucose in patients with inadequate blood glucose control through diet, exercise and lifestyle interventions alone. Its specific clinical applications are as follows:
Monotherapy for T2DM with inadequate lifestyle interventionIt is the first-choice second-generation sulfonylurea drug for adult T2DM patients whose fasting and postprandial blood glucose remain above the target range after 3–6 months of strict diet control, regular physical exercise and weight management (especially for overweight or obese patients with mild to moderate hyperglycemia). Immediate-release glipizide is preferred for patients with prominent postprandial hyperglycemia (PPHG), while extended-release glipizide is more suitable for patients with poor control of fasting blood glucose (FBG) or those who require once-daily administration for better medication compliance.
Combination therapy for refractory T2DMFor T2DM patients with insufficient blood glucose control by monotherapy with other oral hypoglycemic agents (e.g., metformin, α-glucosidase inhibitors, thiazolidinediones) or glucagon-like peptide-1 (GLP-1) receptor agonists, glipizide can be combined with these drugs to achieve synergistic hypoglycemic effects. The combination of glipizide (promoting insulin secretion) and metformin (improving insulin sensitivity/reducing hepatic glucose production) is a classic first-line combined regimen for T2DM, which can effectively control both FBG and PPHG, reduce the dosage of a single drug, and lower the risk of adverse reactions such as hypoglycemia and gastrointestinal discomfort. It can also be combined with SGLT-2 inhibitors for patients with T2DM complicated by heart failure or chronic kidney disease, under close blood glucose monitoring.
Blood glucose management for special populations with T2DMIt is suitable for elderly T2DM patients (65–80 years old) with preserved pancreatic β-cell function and no severe comorbidities (e.g., severe liver/kidney dysfunction, cardiovascular and cerebrovascular diseases). The extended-release formulation is the first choice for the elderly due to its stable blood glucose control and low risk of acute hypoglycemia; the dosage needs to be titrated from the minimum effective dose to avoid over-hypoglycemia caused by age-related decline in renal clearance and reduced glucose tolerance. It is also applicable to adult T2DM patients with mild to moderate hepatic/renal insufficiency (excluding severe insufficiency), with dosage adjustment based on liver and kidney function test results and blood glucose monitoring.
Adjuvant blood glucose control for T2DM in the perioperative periodFor T2DM patients undergoing minor elective surgery (excluding major abdominal or cardiothoracic surgery) who cannot use insulin for temporary blood glucose control, glipizide (especially the immediate-release formulation) can be used for short-term adjuvant blood glucose management during the perioperative period (with dose reduction), combined with diet adjustment, to maintain blood glucose within a safe range and reduce the risk of surgical complications caused by hyperglycemia.
Key Contraindications for Use: Glipizide is not applicable to type 1 diabetes mellitus (T1DM) patients (no functional pancreatic β-cells), patients with diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) (insulin is the first choice), and patients with gestational diabetes (GDM) (insulin is the standard treatment to avoid fetal adverse effects).
FAQ
Q1. Can I get a free sample?
We can send you a samll free sample, and you only need to pay for the shipping cost.
Q2. What is the HyperChem payment term?
T/T in advance
LC at sight
DP at sight
Bank transfer
PayPal
Bitcoin...
Q3. What is HyperChem shipment policy?
Our policy is to strive for the quickest shipment time possible.
For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.
Q4. What is HyperChem shipment term?
By Express
FedEx UPS DHL EMS
Fast: 3-7 days around, high cost, door to door service
By Air
Suitable for more than 50kg
Fast: 3-7 days, hight cost, port to port, professional broker needed
By Sea
Suitable for more than 500kg
Fast: 7-45 days, low cost, port to port, professional broker needed
We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.
Q5. What HyperChem will provide after shipment?
For sample orders:
After shipment is done, an timely email including:
1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice
For commercial orders:
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.
